Source: https://www.mycancergenome.org/content/clinical_trials/NCT02997995/
Timestamp: 2019-07-18 15:46:11
Document Index: 345887279

Matched Legal Cases: ['art 1', 'art 2', 'art 2', 'art 2', 'art 2', 'art 2', 'art 2']

Clinical Trial: NCT02997995 - My Cancer Genome
NCT02997995
This is an open-label, multicentric, international, phase II trial testing aromatase inhibitors in combination with durvalumab in patients with CD8+ T cell infiltration (>10% CD8+ T cells in the tumor). The trial includes two sequences: The first part of the treatment will consist in 4-6 weeks treatment with immune-attractants; in the second part, CD8+ patients will receive 6 months of durvalumab combined with exemestane.
https://clinicaltrials.gov/show/NCT02997995
Brief Title: Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure
Official Title: A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration After 4-6 Weeks Exposure to Immune-Attractant
ORG STUDY ID: UC-0140/1606
SECONDARY ID: UCBG-105
SECONDARY ID: BIG 16-01
SECONDARY ID: 2016-000764-42
NCT ID: NCT02997995
Immune-attractant Tremelimumab Immune-attractant/lymphocyte activation
Durvalumab MEDI4736 Immune-attractant/lymphocyte activation
The study is conducted in 2 parts:
Part 1: lymphocyte attraction. After the screening phase, the patient will receive
immune-attractant combined with exemestane for six weeks.
As immune-attractants are added over the course of the study, they will appear as subsequent
appendices in the full protocol.
Up to 4 cohorts may be tested sequentially in this design until up to 240 evaluable patients
The first cohort patients will receive tremelimumab (3 mg/kg, single infusion) combined with
exemestane (25 mg daily). In each cohort, an interim analysis will be performed after 30
patients in order to potentially stop the cohort (if less than 25% of patients present >10%
CD8+ cells in the tumor after 3 weeks). If all 4 cohorts are closed and the target number of
56 patients for part 2 has not been reached, additional patients will be recruited and
treated with the best performing immune-attractant treatment based on the part I results.
From the moment 56 patients are included in part 2, no more patients will be entered in part
After three weeks (+/- 3 days), a tumor biopsy will be done. Patients who present >10% CD8+
cells in the tumor after 3 weeks and remain eligible will be included in the second part of
the trial (patients who do not present CD8+ T cells on the 3-weeks biopsy will be treated at
the investigator's choice).
Part 2: lymphocyte activation (anti-PD1 treatment) Four to six weeks after immune-attractant
start, patients having >10% CD8+ cells in the tumor will receive durvalumab 1500 mg Q4W
(equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months.
Part 2 will include two steps. In the first step, we will include 23 patients. If 2 or more
pathological complete responses are observed in these 23 patients, the part 2 will move to
step 2. 33 additional patients will be included in the step 2.
Immune-attractant/lymphocyte activation Experimental After the screening phase, the patient will receive immune-attractant combined with exemestane for six weeks. After three weeks (+/- 3 days), a tumor biopsy will be done. Patients who present >10% CD8+ cells in the tumor after 3 weeks and remain eligible will be included in the second part of the trial i.e. lymphocyte activation. In this second part, patients will receive durvalumab 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months. The pathological response will be checked by surgery.
Immune-attractant
1. Age ≥18 years post-menopausal according to one of the following criteria:
Age > 60 years Or Bilateral ovariectomy Or Age ≤ 60, with an uterus and presenting an
amenorrhea of more than 12 months and FSH and estradiol in the postmenopausal range Or
Age ≤ 60, without an uterus and FSH and estradiol in the postmenopausal range
2. Histologically proven invasive breast cancer eligible to neoadjuvant endocrine therapy
according to multidisciplinary tumor board; Note: Multicentric/multifocal tumors are
allowed if all share the same characteristics.
5. Luminal A patients ER-positive by IHC according to the following criteria (local
assessment): Grade I or II AND ER-positive (≥ 60%) AND Ki67 <20%;
6. Her2-negative by IHC (score 0 or 1+) and/or FISH/CISH negative according to local
7. CD8+ T Cell infiltration defined as >10% cells stained with anti-CD8 mAB by IHC at the
3-week biopsy (applicable for inclusion in part 2 only);
9. World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance
status of 0 or 1 at enrolment;
Hemoglobin ≥9.0 g/dL Absolute neutrophil count ≥1.5 × 109 /L Platelet count ≥100 ×
109/L Serum bilirubin ≤1.5 × the ULN. This will not apply to patients with confirmed
Gilbert's syndrome, who will be allowed in consultation with their physician.
ALT and AST ≤2.5 × ULN; Adequate renal function as determined by CKD-EPI formula
(using actual body weight)
11. Willingness and ability to comply with scheduled visits, treatment plan, laboratory
tests, and other trial procedures;
12. Written informed consent obtained prior to performing any protocol-related procedures,
2. No prior exposure to immune-mediated therapy including, but not limited to, other
anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-programmed cell death ligand 2
(anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines;
3. Any concurrent chemotherapy, investigational product (IP), biologic therapy for cancer
5. Major surgical procedure (as defined by the Investigator) within 28 days prior to the
inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis with the
syndrome, or Wegener syndrome (granulomatosis with polyangiitis), Graves' disease,
rheumatoid arthritis, hypophysitis, uveitis, etc within the past 3 years prior to the
start of treatment. The following are exceptions to this criterion:
-  Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone
replacement or psoriasis not requiring systemic treatment;
8. Any condition that, in the opinion of the Investigator, would interfere with the
evaluation of investigational product or interpretation of patient safety or study
results, including ongoing or active infection, symptomatic congestive heart failure,
uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial
lung disease, or psychiatric illness/social situations that would limit compliance
with study requirement, substantially increase risk of incurring adverse events from
investigational products, or compromise the ability of the patient to give written
9. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms;
12. Active infection including hepatitis B, hepatitis C, or human immunodeficiency virus
13. Current or prior use of immunosuppressive medication within 14 days before the first
dose. The following are exceptions to this criterion:
-  Systemic corticosteroids at physiologic doses not exceeding 10 mg/day of
Note: Patients, if enrolled, should not receive live vaccine during the study and up
15. Known allergy or hypersensitivity to any medicinal product used in the trial or any
Description: Response at surgery
Measure: Number of CD8+ T cell
Time Frame: at biopsy (3 weeks)
Description: exam at biopsy and comparison between biopsy and Baseline biopsy rates
Time Frame: after 6 months of Durvalumab
Description: Clinical exam
Measure: Assessment of Ki67
Time Frame: at surgery
Description: measure of Ki67
Time Frame: 1 year and 8 months
Description: CTC AE v4.03
Measure: Predictive value of Mutational load for efficacy of Durvalumab
Time Frame: on baseline biopsy and blood samples
Description: exome sequencing on baseline samples
Measure: Predictive value of PDL1 expression for the efficacy of Durvalumab
Time Frame: on baseline biopsy and biopsy at 3 weeks
Description: correlate Immune infiltrate intensity with the proportion of tumor cells expressing PD-L1 by Ventana SP263 assay
T2-T4 Breast cancer
Immune-attractants
lymphocytes activation